172 related articles for article (PubMed ID: 20390426)
1. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer.
Hori S; Jabbar T; Kachroo N; Vasconcelos JC; Robson CN; Gnanapragasam VJ
J Cancer Res Clin Oncol; 2011 Feb; 137(2):235-41. PubMed ID: 20390426
[TBL] [Abstract][Full Text] [Related]
2. Nadir PSA level and time to PSA nadir following primary androgen deprivation therapy are the early survival predictors for prostate cancer patients with bone metastasis.
Sasaki T; Onishi T; Hoshina A
Prostate Cancer Prostatic Dis; 2011 Sep; 14(3):248-52. PubMed ID: 21502970
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes and nadir prostate-specific antigen (PSA) according to initial PSA levels in primary androgen deprivation therapy for metastatic prostate cancer.
Kitagawa Y; Ueno S; Izumi K; Kadono Y; Mizokami A; Hinotsu S; Akaza H; Namiki M
World J Urol; 2016 Mar; 34(3):319-27. PubMed ID: 26089252
[TBL] [Abstract][Full Text] [Related]
4. Nadir prostate-specific antigen (PSA) level and time to PSA nadir following primary androgen deprivation therapy as independent prognostic factors in a Japanese large-scale prospective cohort study (J-CaP).
Kitagawa Y; Ueno S; Izumi K; Mizokami A; Hinotsu S; Akaza H; Namiki M
J Cancer Res Clin Oncol; 2014 Apr; 140(4):673-9. PubMed ID: 24522405
[TBL] [Abstract][Full Text] [Related]
5. Nadir PSA level and time to nadir PSA are prognostic factors in patients with metastatic prostate cancer.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Urol; 2014 Apr; 14():33. PubMed ID: 24773608
[TBL] [Abstract][Full Text] [Related]
6. Risk factors of PSA progression and overall survival in patients with localized and locally advanced prostate cancer treated with primary androgen deprivation therapy.
Tomioka A; Tanaka N; Yoshikawa M; Miyake M; Anai S; Chihara Y; Okajima E; Hirayama A; Hirao Y; Fujimoto K
BMC Cancer; 2015 May; 15():420. PubMed ID: 25990314
[TBL] [Abstract][Full Text] [Related]
7. Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).
Kawakami J; Cowan JE; Elkin EP; Latini DM; DuChane J; Carroll PR;
Cancer; 2006 Apr; 106(8):1708-14. PubMed ID: 16544313
[TBL] [Abstract][Full Text] [Related]
8. Patterns of Declining Use and the Adverse Effect of Primary Androgen Deprivation on All-cause Mortality in Elderly Men with Prostate Cancer.
Sammon JD; Abdollah F; Reznor G; Pucheril D; Choueiri TK; Hu JC; Kim SP; Schmid M; Sood A; Sun M; Kibel AS; Nguyen PL; Menon M; Trinh QD
Eur Urol; 2015 Jul; 68(1):32-9. PubMed ID: 25457017
[TBL] [Abstract][Full Text] [Related]
9. Cutoff value of time to prostate-specific antigen nadir is inversely correlated with disease progression in advanced prostate cancer.
Sasaki T; Onishi T; Hoshina A
Endocr Relat Cancer; 2012 Oct; 19(5):725-30. PubMed ID: 22807499
[TBL] [Abstract][Full Text] [Related]
10. Prostate-specific antigen nadir and cancer-specific mortality following hormonal therapy for prostate-specific antigen failure.
Stewart AJ; Scher HI; Chen MH; McLeod DG; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Sep; 23(27):6556-60. PubMed ID: 16170163
[TBL] [Abstract][Full Text] [Related]
11. Detectable prostate-specific antigen Nadir during androgen-deprivation therapy predicts adverse prostate cancer-specific outcomes: results from the SEARCH database.
Keto CJ; Aronson WJ; Terris MK; Presti JC; Kane CJ; Amling CL; Freedland SJ
Eur Urol; 2014 Mar; 65(3):620-7. PubMed ID: 23245686
[TBL] [Abstract][Full Text] [Related]
12. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
13. Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.
Scholz M; Lam R; Strum S; Jennrich R; Johnson H; Trilling T
Urology; 2007 Sep; 70(3):506-10. PubMed ID: 17905106
[TBL] [Abstract][Full Text] [Related]
14. The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.
Soga N; Hori Y; Ogura Y; Hayashi N; Sugimura Y
Jpn J Clin Oncol; 2012 Jun; 42(6):534-40. PubMed ID: 22438406
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of J-CAPRA score for high-risk prostate cancer patients treated with carbon ion radiotherapy plus androgen deprivation therapy.
Akakura K; Tsuji H; Suzuki H; Ichikawa T; Ishikawa H; Okada T; Kamada T; Harada M; Tsujii H; Shimazaki J
Jpn J Clin Oncol; 2014 Apr; 44(4):360-5. PubMed ID: 24585931
[TBL] [Abstract][Full Text] [Related]
16. The slope associated with nadir prostate-specific antigen is prognostically significant in men with hormone-sensitive prostate cancer after primary androgen deprivation therapy.
Zhenhao Z; Xiaofeng C; Hao J; Ming Y; Hongtao Z; Wenrui H; Cheng Z; Xiaochen Z; Gongxian W
Cancer Med; 2022 Sep; 11(17):3251-3259. PubMed ID: 35307955
[TBL] [Abstract][Full Text] [Related]
17. Association of time to prostate-specific antigen nadir and logarithm of prostate-specific antigen velocity after progression in metastatic prostate cancer with prior primary androgen deprivation therapy.
Teoh JY; Tsu JH; Yuen SK; Chiu PK; Chan SY; Wong KW; Ho KL; Hou SS; Ng CF; Yiu MK
Asian J Androl; 2017; 19(1):98-102. PubMed ID: 26585698
[TBL] [Abstract][Full Text] [Related]
18. [Prognostic factors for PSA relapse of prostate cancer after endocrine therapy].
Nakata S; Nakano K; Takahashi H; Shimizu K; Kawashima K
Nihon Hinyokika Gakkai Zasshi; 2005 Nov; 96(7):685-90. PubMed ID: 16363654
[TBL] [Abstract][Full Text] [Related]
19. Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy.
Zelefsky MJ; Lyass O; Fuks Z; Wolfe T; Burman C; Ling CC; Leibel SA
J Clin Oncol; 1998 Oct; 16(10):3380-5. PubMed ID: 9779716
[TBL] [Abstract][Full Text] [Related]
20. Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure.
D'Amico AV; Moul JW; Carroll PR; Cote K; Sun L; Lubeck D; Renshaw AA; Loffredo M; Chen MH
J Natl Cancer Inst; 2004 Apr; 96(7):509-15. PubMed ID: 15069112
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]